- Home
- Browse
- National Institutes of Health
- PAR-25-183
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
- Deadline
- 2026-10-15
- 42 days left
- Award ceiling
- —
- Awards
- —
- Posted
- 2024-11-26
Summary
NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. […]
The rest of this announcement — free with an account
- →The full announcement text, not the first two sentences
- →All 3 review criteria reviewers score this against, extracted from this announcement
- →Whether you are eligible — career stage, institution type, and the windows that close before the deadline does
- →What similar funded projects received, from 219,000 past awards
No card required. Browsing and your first match are free.
More from National Institutes of Health
See all →NIH Director’s Transformative Research Award for Individual and Group Science (R01 Clinical Trial Optional)
The NIH Director's Transformative Research Award supports collaborative investigative teams or individual scientists who propose unusually bold and innovative research projects, which, if successful, would have a major impact in a broad area of relevance to the NIH.
3 review criteria on fileNIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileNIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
S. technology development and commercialization.
7 review criteria on fileNIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileAlso in aging
Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
Purpose This Notice of Funding Opportunity (NOFO) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-Designated Cancer Centers. NCI-Designated Cancer Centers serve as major sources of discovery into the nature of cancer and of the development of more effective approaches to prevention, diagnosis, and therapy.
11 review criteria on fileResource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed)
Experimental research models are indispensable for studying the genetic basis and pathobiological mechanisms underlying human diseases, identifying drug targets, and developing effective preventive and therapeutic approaches.
7 review criteria on fileSingle Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)
his is a non-competitive funding opportunity intended to fund a single award.
9 review criteria on fileOfficial announcement: https://grants.nih.gov/grants/guide/pa-files/PAR-25-183.htmlSource: nih_guide+grants_gov. Always confirm dates with the funder.